Multiple Myeloma Treatment: Insights on Darzalex, Its Mechanism, and Additional Information
Darzalex and Darzalex Faspro are two treatments for multiple myeloma, a cancer that affects plasma cells, a type of white blood cell found in the bone marrow. Both drugs belong to the monoclonal antibodies drug class and contain the same active drug, daratumumab. However, they differ in their formulation and administration route.
Darzalex is an intravenous (IV) formulation, given as a slow IV infusion, often requiring several hours. On the other hand, Darzalex Faspro is a subcutaneous formulation that combines daratumumab with hyaluronidase (ENHANZE® technology), allowing it to be administered via a shorter injection under the skin. This change significantly reduces administration time and chair time for patients, making treatment more convenient.
The dosing schedules for Darzalex vary depending on the stage of multiple myeloma. For the initial eight weeks, patients receive one dose every week (eight total doses). From weeks 9 to 24, the dosing schedule changes to one dose every 2 weeks (eight total doses). Starting from week 25, the dosing schedule for both multiple myeloma and light chain amyloidosis is one dose every 4 weeks.
It's important to note that Darzalex is not a cure for multiple myeloma. Both Darzalex and Darzalex Faspro are prescribed to adults who have multiple myeloma and are newly diagnosed or have had previous treatments. The dosage of Darzalex is calculated using body weight and is typically 16 milligrams per kilogram of body weight.
The cost of Darzalex is based on several factors, including the prescribed treatment regimen, insurance plan, and location. While Darzalex is not available as a biosimilar, biologics have biosimilars which tend to cost less than brand-name medications.
Both forms of Darzalex are approved for treatment of multiple myeloma, including in combination with other therapies for newly diagnosed and relapsed/refractory patients, as well as for light chain (AL) amyloidosis in combination therapy. Darzalex Faspro also has a specific recent approval in Europe for monotherapy in high-risk smouldering multiple myeloma due to its more convenient administration, facilitating early intervention.
However, both treatments come with potential side effects. Mild side effects associated with Darzalex include upper respiratory infection, diarrhea or constipation, fatigue, nausea, cough, fever or chills, shortness of breath, back or joint pain, decreased appetite, pain in your arms or legs, headache, and hypertension. Serious side effects associated with Darzalex include infusion-related reactions, blood disorders, pneumonia, and allergic reactions.
In conclusion, while Darzalex and Darzalex Faspro share the same active drug and similar clinical indications for multiple myeloma and light chain amyloidosis treatment, they differ in their mode of delivery, duration and complexity of administration, and patient convenience. It's crucial for patients to discuss their treatment options with their healthcare providers to make informed decisions about their care.
Science plays a significant role in the development and use of Darzalex and Darzalex Faspro, two treatments for multiple myeloma, a type of cancer affecting medical-conditions like plasma cells. Treatmentseekers often weigh the benefits of these options, considering factors such as treatment schedules, side effects, and health-and-wellness implications, while discussing with their healthcare providers to make informed decisions.
